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patients with an inadequate response to disease
modifying anti-rheumatic drugs: a meta-analysis
of randomized double-blind controlled studies
Asres BerhanAbstract
Background: This meta-analysis was conducted to determine the efficacy, safety and tolerability of tofacitinib in
the treatment of rheumatoid arthritis in patients with an inadequate response or intolerance to at least one of the
nonbiologic or biologic disease-modifying antirheumatic drugs (DMARDs).
Methods: Electronic based literature search was conducted in the databases of HINARI (Health InterNetwork Access
to Research Initiative), MEDLINE and Cochrane library. The studies included in the meta-analysis were double-blind
randomized clinical trials that were conducted in treatment-refractory or intolerant patients with rheumatoid
arthritis. The odds ratios (OR), standardized mean differences (SMD) and the 95% confidence intervals (95% CI) were
determined by using the random effects model. Heterogeneity among the included studies was evaluated by I2
statistics.
Results: The odds of tofacitinib treated patients who met the criteria for an at least a 20% improvement in the
American College of Rheumatology scale (ACR 20) was more than 4 times higher than placebo treated patients
(overall OR = 4.15; 95% CI, 3.23 to 5.32). Even though the discontinuation rate due to adverse events was not
different from placebo groups, tofacitinib was associated with infections (overall SMD = 1.96, 95% CI = 1.428 to
2.676), reduction in neutrophil counts (overall SMD = −0.34, 95% CI = −0.450 to −0.223) and elevated levels of LDL
cholesterol and liver enzymes.
Conclusions: Tofacitinib was effective in the treatment of active rheumatoid arthritis in patients with an inadequate
response or intolerance to at least one DMARDs. However, treatment with tofacitinib was associated with infections
and laboratory abnormalities.
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Rheumatoid arthritis is a progressive autoimmune disease
that results in a systemic chronic inflammation and de-
struction of the joints. Accordingly, the primary aim of
rheumatoid arthritis treatment is to reduce the pro-
gression of the disease and to maximize long-term health-
related quality of life [1]. The prevailing rheumatoid
arthritis treatment approach comprises both non biologic
(conventional) and biologic DMARDs [2].Correspondence: asresb@hu.edu.et
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reproduction in any medium, provided the orThe nonbiologic DMARDs are orally active small mole-
cules; while biologic DMARDs are large proteins which
are available as parenteral formulations. Of the non bio-
logic DMARDs methotrexate is the most widely used
[3,4]. Patients with an inadequate response to methotre-
xate are usually treated with biologic DMARDs such as
tumor necrosis factor (TNF) inhibitors, either as mono-
therapy or in combination with nonbiologics DMARDs
[2]. However, about 20-30% of the patients who were
treated with biologic DMARDs monotherapy or in com-
bination with nonbiologic DMARDs may not meet the
ACR 20 improvement criteria (ACR20) [5-7]. On thehis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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due to adverse events.
Tofacitinib is a novel oral Janus kinase (JAK) inhibitor
that is under investigation as a targeted immunomodula-
tor and disease-modifying therapy in rheumatoid arthritis.
In vitro and in vivo studies have demonstrated its efficacy
in inhibiting osteoclast-mediated structural damage to
arthritic joints [8,9]. Randomized double-blind controlled
dose- ranging (1, 3, 5, 15, 20 and 30-mg) clinical trials
have assessed the efficacy and safety of tofacitinib twice
daily (BID) in treatment-refractory patients with rheuma-
toid arthritis. Most of the clinical trials on tofacitinib have
reported the significant reductions in signs and symptoms
of rheumatoid arthritis and improvement in physical func-
tion with manageable safety [10-13].
Though tofacitinib is approved recently by the food and
drug administration (FDA) of America for the treatment
of rheumatoid arthritis, no published meta-analysis has
yet evaluated its consistent efficacy, safety and tolerability
across studies. Thus the primary aim of this meta-analysis
was to determine the efficacy, safety and tolerability of
tofacitinib in the treatment of rheumatoid arthritis in pa-
tients with inadequate response or intolerance to at least
one of the nonbiologic or biologic DMARDs.Methods
Search strategy
Electronic based literature search was conducted in the
databases of HINARI, MEDLINE and Cochrane library.
Via HINARI, literature search was also conducted on the
websites of major publishers (Elsevier Science-Science
Direct, Wiley-Blackwell, Nature Publishing Group, Oxford
University Press, PsycARTICLES, and Science). Further-
more, the literature search was strengthened by searching
relevant articles from the reference lists of retrieved arti-
cles. During searching the following search terms were
used alone or in an alternate combination with the help
of Boolean operators (AND, OR, and NOT): tofacitinib,
CP-690,550, JAK Inhibitor, rheumatoid arthritis, and
ACR20 response.Inclusion criteria and study selection
The predetermined study inclusion criteria for this meta-
analysis were: 1) double- blind randomized clinical trial
that assessed the efficacy and safety of tofacitinib as
monotherapy or in combination with methotrexate in
patients with rheumatoid arthritis who were on at least
one of the nonbiologic or biologic DMARDs; 2) studies
that recruited patients with rheumatoid arthritis that had
been diagnosed for ≥ 6 months and had active disease on
the basis of the American College of Rheumatology 1987
revised criteria [14]. 3) Studies that were published in
English.The study selection was conducted in two stages. First,
by reviewing the abstracts of all the retrieved literature,
they were categorized as “eligible for full document
review” and “ineligible for full document review”. Se-
condly, the whole document of all the articles categorized
as “eligible for full document review” were reviewed and
categorized as “eligible for meta-analysis” and “ineligible
for meta-analysis”.
Data extraction
After developing a data extraction template, data extrac-
tion was conducted with standard Excel spreadsheets.
From the included studies the following information were
extracted: name of the first author, year of publication,
study design, phase of the trial, duration of therapy, dose,
sample size, name of drug(s) used as background regimen,
ACR20 response rates, least squares means ± standard
errors (SE) or standard deviations (SD) for changes in la-
boratory test results and ACR 20 core component scores,
number of patients who experienced adverse events,
number of patients who discontinued medication due to
adverse events, number of patients with alanine amino-
transferase levels that were greater than one times the
upper limit of the normal range (ALT >1 X ULN), number
of patients with aspartate aminotransferase levels that
were greater than one times the upper limit of the normal
range (AST >1 X ULN) and incidences of infections.Operational definitions
In the included studies ACR 20 was defined as at least a
20% reduction from baseline in the number of both tender
and swollen joints and at least a 20% improvement in three
or more of the five remaining ACR core set measures
(patient’s assessment of pain, level of disability, C-reactive
protein level, global assessment of disease by the patient,
and global assessment of disease by the physician [14].
Whereas, active disease was defined as the presence of 6
or more tender or painful joints (68 joint count) and 6 or
more swollen joints (66 joint count) and either an erythro-
cyte sedimentation rate (ESR) above ULN or a C- reactive
protein (CRP) level >7-mg/liter [14].Data synthesis & statistical analysis
For continues variables where SEs were reported instead
of SDs, values for SDs were computed by multiplying the
SEs with the square root of sample size (SD ¼ SE  ﬃﬃﬃﬃNp ,
where N = sample size). Similarly, when the value of
serum creatinine was reported as μmol/L, it was converted
to mg/dl by dividing the values to 88.4. The efficacy, safety
and tolerability of tofacitinib 3, 5, 10, and 15-mg BID
alone (monotherapy) or in combination with background
methotrexate relative to placebo or placebo with back-
ground methotrexate in the treatment of rheumatoid
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model. The OR and the 95% CI for the number of
patients with: at least a 20% improvement in ACR 20,
ALT > 1 X ULN, AST > 1 X ULN, adverse events, infec-
tions and discontinued treatment due to adverse events
were computed with Mantel-Haenszel method. The
SMD and 95% CIs for the mean changes in: laboratory
test results (hemoglobin, neutrophils, serum creatinine,
HDL cholesterol, and LDL cholesterol) and Health
Assessment Questionnaire–Disability Index (HAQ DI)
were computed using the inverse variance method.
However, since tofacitinib 1-mg BID did not demon-
strate a significant improvement in ACR20 in any of the
included studies, tofacitinib 1-mg BID was excluded
from the meta-analyses.
Heterogeneity among the included studies was
assessed by the chi-squared test (Cochran Q test) and
I2 statistics. When the value of I2 was greater than or
equal to 50%, it was considered as statistically signi-
ficant. To assess the possible sources of heterogeneity
among the included studies, subgroup analysis based
on tofacitinib doses and type of therapy (monotherapy
vs combination therapy) and meta-regression with
two covariates (dose and duration of therapy) were
conducted. Sensitivity analysis was also conducted to
determine the robustness of the overall values and
the change in I2 statistics when any of the included
study was withdrawn (excluded) from the analysis.
Risk of bias of individual studies was evaluated with
the Cochrane risk of bias tool. On the other hand,
publication or disclosure bias was assessed with fun-
nel plots. However, tests for funnel plot asymmetry
were not conducted as recommended in a meta-
analysis that included less than ten studies [15]. All
the statistical analyses were conducted by the Open-
MetaAnalyst software.Figure 1 Flow diagram showing studies selection.Results
Search result
Based on the predetermined inclusion criteria, from the
retrieved 43 publication, only eight double-blind ran-
domized clinical trials [10-13,16-19] were included in
the meta-analysis (Figure 1). Except one study [19] that
was conducted in Japan at multiple sites all the included
studies recruited patients with rheumatoid arthritis
from more than one country. As shown in Table 1, five
of the included studies compared the efficacy, safety and
tolerability of tofacitinib in combination with back-
ground methotrexate against placebo with background
methotrexate regimen [10,12,13,18,19]. While the re-
maining three studies compared tofacitinib mono-
therapy against placebo [11,16,17]. In all the included
studies concomitant medication with stable doses of
low-dose corticosteroids (≤10 mg per day prednisone or
equivalent), nonsteroidal anti-inflammatory drugs and
selective cyclooxygenase-2 inhibitors were allowed for
all treatment groups (tofacitinib or placebo groups).
From all the selected studies a total of 2,513 patients
with rheumatoid arthritis have received one of the four
doses of tofacitinib BID with or without methotrexate
(3, 5, 10 or 15-mg). While 1,770 patients (controls) have
received placebo or placebo with background metho-
trexate. On the other hand, the risk of bias assessment
among the included studies did not demonstrate the
presences of biases in randomization, blinding and se-
lective reporting.
Efficacy
As presented in Figure 2, the odds of tofacitinib treated
patients who met the criteria for an ACR 20 response
was more than 4 times higher than placebo treated
patients (overall OR = 4.15; 95% CI, 3.23 to 5.32). More-
over, to the exception of one study [16], in all the
Table 1 Summary of the randomized controlled trials (RCTs) included in this meta-analysis




Intervention arm-1 Intervention arm-2 Intervention arm-3 Intervention arm-4 Control arm
Kremer JM et al. study 1 [18] 2012 Phase IIb 24-weeks Tofacitinib 3-mg BID +
Methotrexate (N = 68)
Tofacitinib 5-mg BID +
Methotrexate (N = 71)
Tofacitinib 10-mg BID +
Methotrexate (N = 74)
Tofacitinib 15-mg BID +
Methotrexate (N = 75)
Placebo + Methotrexate
(N = 69)
Tanaka Y et al. [19] 2011 Phase II 12-weeks Tofacitinib 3-mg BID +
Methotrexate (28)
Tofacitinib 5-mg BID +
Methotrexate (N = 28)
Tofacitinib 10-mg BID +
Methotrexate (N = 28)
.. Placebo + Methotrexate
(N = 28)








Placebo (N = 59)




.. Placebo (N = 122)
Kremer JM et al. study 2 [17] 2009 Phase IIa 12-weeks . Tofacitinib 5-mg BID
(N = 61)
.. Tofacitinib 15-mg BID
(N = 69)
Placebo (N = 65)
Burmester GR et al. [10] 2013 Phase III 6-months … Tofacitinib 5-mg BID +
Methotrexate (N = 133)
Tofacitinib 10-mg BID +
Methotrexate (N = 134)
.. Placebo + Methotrexate
(N = 132)
van der Heijde D et al. [12] 2013 Phase III 24-month .. Tofacitinib 5-mg BID +
Methotrexate (N = 321)
Tofacitinib 10-mg BID +
Methotrexate (N = 316)
.. Placebo + Methotrexate
(N = 160)
van Vollenhoven RF et al. [13] 2012 Phase III 12-month .. Tofacitinib 5-mg BID +
Methotrexate (N = 204)
Tofacitinib 10-mg BID +
Methotrexate (N = 201)
.. Placebo + Methotrexate
(N = 108)


















Figure 2 Mantel-Haenszel odds ratio of at least a 20% improvement in the American College of Rheumatology scale (ACR 20).
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receiving all tofacitinib dosages ≥ 3-mg BID was signi-
ficantly greater than those who received placebo. Never-
theless, the subgroup odds ratios in the subgroups of
tofacitinib 10-mg (subgroup OR = 4.3; 95% CI, 3.023 to
6.376) and 15-mg (subgroup OR = 6.06; 95% CI, 2.383
to 15.428) was higher than tofacitinib 3-mg (subgroup
OR = 4.06; 95% CI, 1.340 to 12.305) and 5-mg (subgroup
OR = 3.55; 95% CI, 2.435 to 5.169) treated groups.
Heterogeneity testing has unveiled the presence of sig-
nificant inconsistency (heterogeneity) among the included
studies (I2 = 66%). The subgroup analysis showed, the
variations in the types of therapy (tofacitinib monotherapy
vs tofacitinib combined with methotrexate) among theincluded studies was not enough to explain the sources of
heterogeneity. The treatment outcomes with tofacitinib
monotherapy were not significantly different from the
combination of tofacitinib with background methotrexate.
Similarly, linear meta-regressions based on the duration of
therapy and doses of tofacitinib did not show a significant
variation in the therapeutic outcome across studies. How-
ever, sensitivity analysis has confirmed the robustness of
the overall value; when any of the study was excluded
from the analysis the overall odds ratio swings within the
range of 3.63 to 4.79.
The meta-analysis of change in HAQ-DI scores from
baseline presents further evidence that supports the
efficacy of tofacitinib in the treatment of rheumatoid
Berhan BMC Musculoskeletal Disorders 2013, 14:332 Page 6 of 11
http://www.biomedcentral.com/1471-2474/14/332arthritis (Figure 3). This is to mean, a statistically sig-
nificant improvement in HAQ-DI scores were seen in
patients who were on tofacitinib than placebo treated pa-
tients (overall SMD= −0.62, 95% CI = −0.735 to −0.506).
Furthermore, in all the included studies, patients who
were treated with a greater than or equal to 5-mg of tofa-
citinib BID have shown a statistically significant reduction
in HAQ- DI scores. Heterogeneity testing showed no
significant variation among the included studies.
Safety and tolerability
As shown in Figure 4, the proportion of infections was
higher in the tofacitinib treated groups than in the placebo
groups (overall SMD= 1.96, 95% CI = 1.428 to 2.676).
Nonetheless, unlike in the subgroups of tofacitinib 10-mg
(subgroup SMD= 3.08, 95% CI = 1.694 to 5.570) and
15-mg (subgroup SMD= 1.97, 95% CI = 1.088 to 3.558),
the proportion of infections in the subgroups of tofacitinibFigure 3 Standardize mean difference of change in the Health Assess3-mg (subgroup SMD= 1.64, 95% CI = 0.858 to 3.142) and
5-mg (subgroup SMD= 1.52, 95% CI = 0.644 to 3.594)
were not significantly different from placebo.
Whilst, with a significant heterogeneity (I2 = 52%), tofa-
citinib treatment was significantly associated with re-
duction in neutrophil counts (overall SMD= −0.34, 95%
CI = −0.450 to −0.223) (Figure 5). The subgroups SMDs
were not significant in the subgroups of tofacitinib 3-mg
and 15-mg; but the numbers of studies in the subgroups
were very small (only 2 studies in both subgroups).
On the contrary, the mean hemoglobin level has in-
creased significantly from baselines in tofacitinib treated
groups (overall SMD = 0.11, 95% CI = 0.130 to 0.210)
(see Additional file 1). Even though the overall SMD was
statistically significant, the mean hemoglobin level was
increased significantly only in the subgroup of tofacitinib
5-mg (subgroup SMD = 0.22, 95% CI = 0.039 to 0.392).
Similarly, mean serum creatinine (overall SMD = 0.24,ment Questionnaire–Disability Index (HAQ DI) scores.
Figure 4 Mantel-Haenszel odds ratio of patients reporting treatment emergent infections.
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cholesterol (overall SMD= 1.01, 95% CI = 0.332 to 1.682)
(see Additional file 3), and LDL-cholesterol (overall SMD=
0.95, 95% CI = 0.337 to 1.555) (see Additional file 4) levels
have increased significantly in tofacitinib treated groups.
The significant increments in mean serum creatinine,
HDL- cholesterol, and LDL-cholesterol levels were con-
sistent in tofacitinib 5-mg and 10-mg treated groups.
Furthermore, a significant number of patients with
ALT >1 X ULN (overall OR = 1.7; 95% CI, 1.29 to 2.46)
(see Additional file 5) and AST>1 X ULN (overall OR =
2.19; 95% CI, 1.50 to 3.19) (see Additional file 6) were
reported among tofacitinib treated groups. Yet, unlike in
the subgroups of 10-mg and 15-mg the number of patients
who were treated with tofacitinib and had elevated
levels of both liver enzymes (ALT and AST) in the
subgroup of 3-mg were not significantly different from
placebo treated. In the 5-mg subgroup, a significant
number of patients have had an increased level of AST
level but not ALT level.
But, as presented in Figure 6, the comparison based on
the number of patients who discontinued treatment due
to adverse events did not show a significant difference(overall SMD= 1.27, 95% CI = 0.949 to 1.700). This is to
mean, the number of patients who discontinued medica-
tion because of treatment-emergent adverse events in the
tofacitinib treated groups was not significantly different
from placebo treated groups. As shown on the forest plot,
patients who were treated with tofacitinib 15-mg BID was
more likely to discontinue medication than those patients
who were on other smaller doses of tofacitinib.
Discussion
This meta-analysis has demonstrated the efficacy of tofa-
citinib in the treatment of active rheumatoid arthritis in
patients with an inadequate response to at least one
DMARDs. That is, although all the recruited patients
with rheumatoid arthritis had an inadequate response or
intolerance to at least one DMARDs and had active
disease on the basis of the ACR 1987 revised criteria, a
significant improvement in physical functions and a
significant reduction in the signs and symptoms of the
disease were seen in tofacitinib treated patients.
ACR20 response rates and change in HAQ-DI were sig-
nificant in all tofacitinib treatment groups ≥ 3-mg (3, 5, 10
or 15-mg) BID than placebo groups. However, there was a
Figure 5 Standardize mean difference of change in neutrophils count from baseline (1000/mm3).
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sensitivity analysis has demonstrated the stability of the
pooled values. Accordingly the conclusiveness of the
results (ACR20 response rates and change in HAQ-DI)
of this meta-analysis did not seem compromised. When
there was a significant heterogeneity among the included
studies whilst the number of included studies was small,
the robustness of the pooled values was best assessed with
sensitivity analysis [20].
Tofacitinib monotherapy was as effective as tofacitinib
with background methotrexate. However, this finding
(tofacitinib monotherapy vs tofacitinib in combination
with methotrexate) must be interpreted with great cau-
tion. Most of the studies which evaluated the efficacy of
tofacitinib in combination with methotrexate recruited
patients with a criterion of “inadequate response to at
least one nonbiologic or biologic disease-modifying drug”
[13,18,19]. In contrary, studies which compared the
efficacy of tofacitinib monotherapy against placebo did
not clearly state this criterion [11,16,17]. As a result, the
disease state in the recruited patients may be at the earlier
stage and could respond better to treatment. Additionally, aprevious systematic review and meta-analysis of combin-
ation and monotherapy treatments in DMARD-experienced
patients with rheumatoid arthritis has shown the superiority
of combination therapy to monotherapy [21].
Even though the primary studies reported the manage-
able safety profile of tofacitinib over the treatment periods
[10,16,18,19], this meta-analysis has established the signifi-
cant association of tofacitinib with infections, decreased
level of neutrophil and increased levels of hemoglobin,
creatinine and liver enzymes (ALT and AST). Similarly, an
increase in HDL and LDL cholesterol were observed in
patients with rheumatoid arthritis who were treated with
tofacitinib.
Though subgroup analysis did not show a significant
difference when tofacitinib was used as monotherapy
and in combination with background methotrexate, the
significant association of tofacitinib with infection and
laboratory abnormalities could also be partly attributed
to methotrexate. Previous studies have confirmed the as-
sociation of methotrexate with infections, hematological
problems and hepatotoxicity [22-25]. Still, all the in-
cluded studies in the meta-analysis have allowed stable
Figure 6 Mantel-Haenszel odds ratio of patients who discontinued the treatment due to treatment-emergent adverse events.
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men; thus costicosterioids could also have contributed
for the tofacitinib associated infection and immune sup-
pressions [26,27]. While, as verified by a randomized
double- blind study, the elevated level of LDL choles-
terol in tofacitinib treated patients with rheumatoid
arthritis seem to be managed by adding statins to the
regimens [28].
Nevertheless, this meta-analysis has also shown that
the number of tofacitinib treated patients who discon-
tinued medication due to adverse events were not differ-
ent from placebo treated groups. Moreover, the included
studies in this meta-analysis were not primarily designed
to assess tofacitinib related adverse events. As a result,
the significant association of tofacitinib with infections
and laboratory abnormalities might not be conclusive. Ameta-analysis including studies which were not designed
to assess adverse events and have had small sample sizes
may not have an adequate power to test rare adverse
events [29].
As limitations, first, this meta-analysis has noted a sig-
nificant heterogeneity among the included studies. The
possible explanation for the significant heterogeneity
among the included studies could be: 1) the differences in
the baseline demographic and clinical characteristics of the
patients recruited in the studies. 2) The variation in the
duration of therapy and the drug regimens (tofacitinib
monotherapy vs tofacitinib with background methotrexate)
across studies. Nonetheless, these assumptions were not
supported by either the subgroup analysis or meta-regres-
sion; that is to say, the treatment outcome did not seem to
be affected by the duration of therapy and by the use of
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trexate. Second, since most of the included studies did not
report values for ACR50, and ACR70 responses, meta- ana-
lyses were not conducted with these outcome indicators.
Third, all the primary studies included in this meta-analysis
were sponsored by a pharmaceutical company. Studies
sponsored by pharmaceutical companies were more likely
to have outcomes favoring the sponsor interests [30,31].
Fourth, this meta-analysis did not to incorporate studies
written in other languages.
Conclusion
In conclusion, tofacitinib monotherapy or in combination
with background methotrexate was effective in the treat-
ment of active rheumatoid arthritis in patients with an in-
adequate response or intolerance to at least one of the
nonbiologic or biologic DMARDs. Additionally, the num-
ber of patients who discontinued medication in the tofa-
citinib treatment groups was not different from placebo
groups. However, treatment with tofacitinib was asso-
ciated with infections and laboratory abnormalities. Ac-
cordingly, further studies that are primarily designed to
assess tofacitinib related adverse events and have a longer
duration of therapy with a large number of patients are
warranted.
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